Le Lézard
Classified in: Health, Business
Subject: LIC

A. Menarini Diagnostics Signs Exclusive Supply and Distribution Agreement with PlexBio


TAIPEI, Taiwan, and FLORENCE, Italy, June 26, 2019 /PRNewswire-PRWeb/ -- Taipei-based PlexBio Co., Ltd. and Florence-based A. Menarini Diagnostics, announced they have entered into a supply and distribution agreement for PlexBio's IntelliPlextm diagnostic instrument platform and reagent kits for oncology and infectious disease testing. Under the agreement, A. Menarini Diagnostics will be the exclusive distributor for PlexBio's kits portfolio and manage all marketing, sales and support activities across western Europe, the Middle East and Australia. The aim is to advance both companies' position in molecular diagnostics with a unique opportunity to expand into new markets and drive future growth.

PlexBio's IntelliPlextm instrument platform and Precision Image Code (?Codetm) MicroDisc technology has enabled the development of a series of high complexity multiplex assays for cost-effective Companion Diagnostic (CDx) testing in cancer management for gene mutations and gene rearrangements. Under the exclusive distribution agreement for the IntelliPlextm system, PlexBio will enable A. Menarini Diagnostics to offer more personalized health care solutions for optimized treatment outcomes for cancer patients. A. Menarini Diagnostics brings to the partnership its deep and proven experience in expanding IVD markets along the entire value chain and will dedicate sales, customer service, marketing, and support team staff to the commercialization of PlexBio's product line. Under the agreement, branding under A. Menarini Diagnostics' label and future collaboration on the development of new applications for liquid biopsy are anticipated.

"Thanks to this agreement Menarini will be able to offer a complete solution in the area of precision oncology," said Fabio Piazzalunga, General Manager of A. Menarini Diagnostics and President of Menarini Silicon Biosystems. "The IntelliPlextm product line, in combination with our established CellSearch® and DEPArraytm products for single cells isolation and characterization, will enhance our capability to provide molecular information both from liquid and solid biopsies. We believe that Menarini will play a pivotal role in personalized medicine to support clinicians and, most of all, improve patients' care"

Dean Tsao, Chairman and Chief Executive of PlexBio said: "We are excited to announce this important partnership with A. Menarini Diagnostics which will provide further momentum for our business. We anticipate both partners will benefit from the natural synergies with several of Menarini's existing product offerings and, by putting high complexity molecular information at the focus of diagnostic testing, PlexBio and Menarini together will help transform the delivery of care for patients."

About A. Menarini Diagnostics: A. Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded in 1886. Today it is present in 136 countries throughout the world, it counts 17,632 employees and has a 2018 turnover of ? 3.6 billion.

For further information, please visit https://www.menarinidiagnostics.com

Contact Information:
A. Menarini Diagnostics S.r.l.
Via dei Sette Santi, 3 - 50131
Florence, Italy
Tel. +39. 055. 56801

About Menarini Silicon Biosystems: Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley (PA), USA, develops innovative technologies and products that help researchers understand the biological complexity of disease through the study of single cells.

For further information, please visit https://www.siliconbiosystems.com

Contact Information:
Menarini Silicon Biosystems
Via G. Di Vittorio 21b/3
Castel Maggiore (Bologna)
Tel. +39. 051. 9944100

About PlexBio Co., Ltd.: The company established in 2010, designs, develops and manufactures IVD products and instrumentation from its headquarters in Taipei, Taiwan and its affiliate location in Jiangsu Province, China. PlexBio has also established an Innovative Technology Center in South San Francisco, CA, USA. The company is a listed company on the Taiwan emerging stock market (6572:TT).

For further information, please visit http://www.plexbio.com

Contact Information:
PlexBio, Co., Ltd.
Address: 6F-1, No. 351, Yangguang St., Neihu District, Taipei City 11491, Taiwan
Tel: +886-2-2627-5878
Fax: +886-2-2627-5979
E-mail: contact(at)plexbio(dot)com

 

SOURCE PlexBio Co., Ltd.


These press releases may also interest you

at 07:15
Fiserv, Inc. , a leading global provider of payments and financial services technology solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 GAAP Results GAAP revenue for the company increased 7% to $4.88...

at 07:15
BlackSky Technology Inc. will host a conference call to discuss first quarter 2024 financial results and its business outlook on Wednesday, May 8, 2024, at 8:30 a.m. EDT. A press release with BlackSky's financial results will be released in advance...

at 07:15
Univar Solutions, LLC ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, announced today that it is expanding its partnership with Dow to distribute construction silicone...

at 07:15
Mill Creek Residential, a leading developer, owner-operator and investment manager specializing in premier rental housing across the U.S., today announced it has broken ground on Modera South Shore Marshfield, a contemporary garden-style community...

at 07:10
908 Devices Inc. , a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will...

at 07:10
Montrose Environmental Group, Inc. (the "Company," "Montrose" or "MEG") announced today that it will issue its first quarter 2024 earnings release on Tuesday, May 7, 2024, after the close of trading on the New York Stock Exchange. You are invited...



News published on and distributed by: